SISU PHARMA, INC.
TARGETING THE STRESS PROTECTION RESPONSE
Sisu Pharma is exploiting the power of the cellular stress response, directly targeting Heat Shock Factor 1 (HSF1) - the key regulator of the heat shock response. Through our innovative HSF1 targeting platform, HI-LiTe, we are advancing selective HSF1 degraders for oncology and activators for neurodegenerative diseases. Our first-in-class compounds have already demonstrated exceptional efficacy in therapy-resistant cancer models, where existing treatments fail. At Sisu, we are not just pushing the boundaries of treatment; we are redefining what's possible in the fight against some of the most challenging diseases.

FOUNDERS AND SCIENTIFIC ADVISORY BOARD
Sisu Pharma is led by a team of world-class scientists with decades of experience and success in basic and translational oncology research and FDA-approved cancer drug development

Sean E. O’Brien, Ph.D.
Founder, Chief Executive Officer

Dennis J. Thiele, Ph.D.
Founder, Chief Scientific Officer, Member Scientific Advisory Board

Jiaoti Huang, M.D. Ph.D.
Founder, Chair Scientific Advisory Board
